Adalimumab

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Non-infectious Intermediate Posterior- or Pan-uveitis

Conditions

Non-infectious Intermediate Posterior- or Pan-uveitis

Trial Timeline

Jul 7, 2022 → Jun 10, 2024

NCT ID

NCT05414201

About Adalimumab

Adalimumab is a approved stage product being developed by AbbVie for Non-infectious Intermediate Posterior- or Pan-uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05414201. Target conditions include Non-infectious Intermediate Posterior- or Pan-uveitis.

What happened to similar drugs?

1 of 6 similar drugs in Non-infectious Intermediate Posterior- or Pan-uveitis were approved

Approved (1) Terminated (2) Active (3)

✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved

❌AIN457 + PlaceboNovartisPhase 3

❌AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3

🔄FAI insert + Sham injectionEyePoint PharmaceuticalsPhase 3

🔄FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserterEyePoint PharmaceuticalsPhase 3

🔄ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic SolutionAldeyra TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05414201	Approved	Completed	Jul 7, 2022	Jun 10, 2024	Non-infectious Intermediate Posterior- or Pan-uveitis
NCT04183608	Approved	Recruiting	Jan 14, 2020	May 1, 2028	Ulcerative Colitis
NCT03311464	Phase 3	Completed	Oct 27, 2017	Apr 21, 2020	Pyoderma Gangrenosum
NCT03261102	Pre-clinical	Active	Jan 17, 2017	Jun 1, 2025	Crohn Disease
NCT02897115	Approved	Terminated	Sep 12, 2016	Dec 21, 2017	Axial Spondyloarthritis
NCT02904902	Phase 3	Completed	Sep 6, 2016	May 30, 2019	Hidradenitis Suppurativa
NCT02668640	Pre-clinical	Completed	May 1, 2016	Aug 13, 2018	Rheumatoid Arthritis
NCT02750800	Pre-clinical	Completed	Apr 7, 2016	Apr 3, 2018	Rheumatoid Arthritis
NCT02739828	Pre-clinical	Completed	Apr 7, 2016	Mar 28, 2018	Hidradenitis Suppurativa
NCT02634541	Approved	UNKNOWN	Jan 1, 2016	Dec 1, 2017	Ankylosing Spondyloarthritis
NCT02632175	Phase 3	Completed	Nov 26, 2015	Apr 8, 2025	Ulcerative Colitis
NCT02533375	Phase 3	Completed	Sep 28, 2015	Jul 20, 2017	Generalized Pustular Psoriasis (GPP)
NCT02499783	Phase 3	Completed	Aug 17, 2015	Dec 15, 2017	Crohn's Disease
NCT02198651	Approved	Completed	Jan 5, 2015	Aug 8, 2018	Rheumatoid Arthritis
NCT02333383	Pre-clinical	Completed	Dec 31, 2014	Aug 8, 2017	Ankylosing Spondylitis
NCT02539849	Pre-clinical	Completed	Dec 1, 2014	Dec 19, 2017	Crohn Disease
NCT02185014	Phase 3	Completed	Aug 12, 2014	Nov 3, 2017	Crohn's Disease
NCT02148718	Approved	Completed	Jun 1, 2014	Jan 1, 2017	Moderate to Severe Crohn's Disease
NCT02065622	Phase 3	Completed	Mar 27, 2014	Nov 11, 2019	Ulcerative Colitis (UC)
NCT02016482	Phase 3	Completed	Jan 1, 2014	Apr 1, 2016	Nail Psoriasis

Competing Products

10 competing products in Non-infectious Intermediate Posterior- or Pan-uveitis

See all competitors

Product	Company	Stage	Hype Score
LFG316 + Conventional Therapy	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
ESK-001	Alumis	Phase 2	21
Topical Prednisolone Acetate 1%	Ocular Therapeutix	Approved	33
FAI insert + Sham injection	EyePoint Pharmaceuticals	Phase 3	34
FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter	EyePoint Pharmaceuticals	Phase 3	34
ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution	Aldeyra Therapeutics	Phase 3	30
NS2 + Prednisolone acetate ophthalmic suspension (1%)	Aldeyra Therapeutics	Phase 2	25